ChanTest is a global leader in the provision of ion channel and GPCR screening to support pharmaceutical discovery and development.
ChanTest scientists were the first to show that hERG was the target for sudden deaths linked to non-cardiac drugs and pioneered the now mandatory hERG assay. Since then they have built upon this foundation to offer the most complete package of services and technologies, that are used by many leading pharmaceutical and biotech companies to discover and characterize new potential drugs for efficacy and safety.
Utilizing their own extensive collection of ion channel and GPCR cell lines, ChanTest can provide services to profile anything from a single compound or a protein/peptide in a Thorough Preclinical Cardiac Safety Study to explore the safety of a lead compound, through to screens of thousands of compounds or proteins and peptides against a novel target.
ChanTest has been named as the “Most trusted Fee-for-Service Provider” for 5 years in a row and also recently as the “Most used Fee-for-Service Provider” for 2 years in a row by HTStec Ion Channel Trends Survey.
In addition to providing their GLP and non-GLP services, ChanTest now offer you the opportunity to use their highly validated target cell lines for in-house research. Choose from either non-replicating frozen and inexpensive EZCells™ for fast convenient secondary screening purposes or purchase a stable cell line for a major project application. Either way you can be sure of the best quality and support.
ChanTest's customers throughout Europe are supported by Cambridge Bioscience. Please contact us by email in the first instance to discuss your needs.